Last checked at 4 Mar 2021 12:46
TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance
TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hutchmed Share News (HCM)
HCM Share
Price
HCM Share
News
HCM Share
Chat
HCM Share
Trades58
HCM
Live RNS
HCM Share
Charts
HCM Level 2
Console
HCM Live
Share Price
HCM Broker
Ratings
HCM Directors
Deals
HCM Financial
Diary
HCM
Fundamentals
HCM Short
Positions
HCM
Media
Hutchmed Information
Share Price Information for Hutchmed (HCM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
300.00
Bid:
293.00
Ask:
299.00
Change:
6.00 (2.07%)
Spread:
6.00 (2.048%)
Open:
299.00
High:
303.00
Low:
298.00
Prev. Close:
290.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.25 Feb 2021 16:19
UK Earnings, Trading Statements Calendar - Next 7 Days
UK Earnings, Trading Statements Calendar - Next 7 Days
Read more11 Jan 2021 14:51
UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020
UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020
Read more30 Dec 2020 22:05
IN BRIEF: Hutchison China Lands "Milestone" China Drug Green Light
IN BRIEF: Hutchison China Lands "Milestone" China Drug Green Light
Read more29 Dec 2020 12:31
Hutchison China Files US FDA Drug Application For Cancer Treatment
Hutchison China Files US FDA Drug Application For Cancer Treatment
Read more17 Nov 2020 19:31
IN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP
IN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP
Read more17 Sep 2020 21:35
UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted
UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted
Read more4 Sep 2020 14:13
Hutchison Chi-Med begins latest trial of fruquintinib
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.
Read more3 Sep 2020 21:27
IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453
IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453
Read more10 Aug 2020 11:04
IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application
IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application
Read more30 Jul 2020 17:56
IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth
IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth
Read more28 Jul 2020 19:48
IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly
IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly
Read more24 Jul 2020 15:45
Hutchison Chi-Med begins phase 1 study of 'HMPL-306'
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.
Read more24 Jul 2020 14:33
Chi-Med Trials Dual Inhibitor For Hematological Cancer
Chi-Med Trials Dual Inhibitor For Hematological Cancer
Read more23 Jul 2020 16:03
UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
Read more